Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma

Sponsor
Guangzhou Women and Children's Medical Center
Study ID
NCT06574698
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
1 Year - 21 Years
Healthy Volunteers
Not accepted

Interventions

  • Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy — DRUG
    Addition of anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy

Study Details

To explore the efficacy of adding anti-GD2 immunotherapy (Naxitamab) at the stage of induction chemotherapy for newly diagnosed high risk neuroblastoma patients. To investigate wether anding Naxitamab in the induction phase will improve the response rate at the end of induction therapy and further improve the overall survival rate.

Key Dates

First listed
Aug 28, 2024
Start date
May 6, 2024
Status verified
Aug 2024
Primary completion
Dec 31, 2029
Completion
Dec 31, 2032

Study Design

Enrollment
64 participants (estimated)

Arms

  • Arm: High risk Neuroblastoma
    High risk Neuroblastoma

Primary Outcome Measure

The number of the patients of VGPR or CR at the end of induction therapy [ Time Frame: 5 years ]

Central Contacts

Find similar trials

Nationwide
Neuroblastoma trialsOncology trialsPediatric oncology trials

Related Studies